Browse studies

Find your next paid study

26,823 recruiting studies available now

Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome

The purpose of this study is to assess the effects of tDCS in combination with TUS for the treatment of pain in subjects with Carpal Tunnel Syndrome. The inves…

Chronic PainCarpal Tunnel Syndrome

Estimated

~$10 – $6,250

Spaulding Rehabilitation HospitalNCT04206215

Validation and Feasibility of Noninvasive Oxygen Delivery Index Monitoring in Cardiac Surgery Patients

This study will establish the feasibility and preliminary validity of real-time oxygen delivery index (DO₂i) monitoring using noninvasive hemoglobin (SpHb, Mas…

Cardiac Surgery

Estimated

~$10 – $750

University of MinnesotaNCT07573306

Phase 2

A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab (REGN2810) in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-…

Head and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell Carcinoma+19 more

Estimated

Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze he…

EczemaAtopic Dermatitis

Estimated

~$10 – $675

National Human Genome Research Institute (NHGRI)NCT00605878

Phase 1

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called …

Hepatocellular Carcinoma

Estimated

~$10 – $7,500

BayerNCT06764316

Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.

Background: People with hearing, balance, and taste, smell, voice, speech, language, and other Ear, Nose, and Throat (ENT) disorders may seek treatment at the…

Hearing LossDeafness

Estimated

~$10 – $675

National Institute on Deafness and Other Communication Disorders (NIDCD)NCT05670496

Phase 4

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study

The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.

ObesityMenopause Hot Flashes

Estimated

~$10 – $6,250

Mayo ClinicNCT07218445

Phase 1

Effect of Neural Constraints on Movement in Stroke

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a strok…

Stroke

Estimated

~$10 – $6,250

Northwestern UniversityNCT06666673

A Prospective Registry of Patients Undergoing Surgical Decompression Followed by Radiation Therapy for Spine Tumors

This is an observational study to evaluate hardware related and oncologic outcomes in adult patients with primary and metastatic spine disease undergoing separ…

Spine TumorSpine MetastasesSpine Cancer

Estimated

~$10 – $750

Ohio State University Comprehensive Cancer CenterNCT07225491

Phase 2

IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjec…

HCC

Estimated

~$10 – $8,750

Geneos TherapeuticsNCT07722741

Phase 1

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advan…

Hepatocellular Carcinoma (HCC)

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07291076

Phase 1

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

HNSCCESCCEsophageal Adenocarcinoma+7 more

Estimated

~$10 – $8,750

Normunity AccelCo, Inc.NCT07182149